The most important signal in the AI trade this month isn't coming from stock charts. It's coming from the bond market, where lenders are starting to charge more for the privilege of funding the data center buildout. CoreWeave's bond yield has climbed above 16%, and Jefferies strategist Christopher Wood put the moment bluntly: the most plausible way the AI capex arms race ends is that the credit card gets taken away.
The pressure is not confined to the weakest borrowers. Credit default swaps on Nvidia debt have risen 76% in a month, Broadcom's are up 49%, and Amazon's have gained 44%. Context matters here: Nvidia's spread sits near 139 basis points, against roughly 298 for Oracle and about 1,100 for CoreWeave, so a big percentage jump from a low base is not the same as genuine distress. Still, investors are demanding more compensation to insure even the strongest balance sheets, and that is a change in tone worth respecting.
The financing machine is also enormous. Goldman Sachs counts five AI bond deals totaling $67 billion since October 29, lifting hyperscaler debt issuance to $296 billion this year, with $440 billion forecast for next year plus another $300 billion at the project level. Yet Goldman also notes that hyperscalers collectively posted negative free cash flow last quarter, because capital spending outran operating cash flow. When a business spends more than it earns and funds the gap with debt, the price of that debt stops being a footnote.
A second pressure is political. Goldman estimates data center moratoriums could affect 45% of planned U.S. capacity, much of it in Texas, Ohio and Georgia, where incoming governors may slow approvals. Bank of America sees AI-related credit issuance rising 31% to $685 billion in 2027, then falling 23% to $531 billion in 2028, and flags a slowdown in projects as a downside risk to even that path.
So what for long-term investors? Nothing here says the AI buildout is collapsing, and the leading hyperscalers still carry strong credit ratings. But the era of cheap, abundant capital for this spending cycle looks like it is ending, and that shifts the question from how much these companies can spend to how much cash those investments will return. Patient investors should pay attention to free cash flow, balance sheet strength and dividend coverage rather than headline growth stories. Companies that fund their growth from their own earnings tend to be the ones still compounding when borrowing costs rise, and the market may be about to put a higher price on that discipline.